Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Lung Cancer

    Glendale, AZ

    Search
    Lung Cancer
    Glendale, AZ
    Show Map
    Map View
    Glendale, AZ
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      168 Lung Cancer Trials near Glendale, AZ

      Power is an online platform that helps thousands of Lung Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      BAY 1895344 + Chemotherapy for Lung Cancer

      Phoenix, Arizona
      This trial tests the safety and best dose of a new drug combined with chemotherapy in patients with advanced solid tumors. The goal is to see if this combination can slow tumor growth more effectively than chemotherapy alone. The new drug blocks enzymes needed for tumor growth, while the chemotherapy drugs kill or stop the tumor cells from dividing. The chemotherapy drugs used in this trial are known to be effective in treating various cancers.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Psychiatric Illness, Others
      Must Not Be Taking:CYP3A4 Inhibitors

      28 Participants Needed

      PD1-Vaxx Immunotherapy for Non-Small Cell Lung Cancer

      Phoenix, Arizona
      This trial tests IMU-201 (PD1-Vaxx), a new treatment for adults with Non-Small Cell Lung Cancer. It aims to help the immune system create antibodies to fight cancer cells more effectively and safely than current treatments.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      24 Participants Needed

      Ceritinib + Nivolumab for Non-Small Cell Lung Cancer

      Scottsdale, Arizona
      This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Other Cancers, Autoimmune Diseases, Others

      57 Participants Needed

      Immunotherapy + Chemotherapy for Small Cell Lung Cancer

      Scottsdale, Arizona
      This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, Active Infection, Others
      Must Not Be Taking:Steroids, Anticonvulsants

      987 Participants Needed

      Toripalimab + Tifcemalimab for Small Cell Lung Cancer

      Goodyear, Arizona
      The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Immunodeficiency, Active Hepatitis, Others

      756 Participants Needed

      Dato-DXd + Durvalumab + Carboplatin for Advanced Non-Small Cell Lung Cancer

      Phoenix, Arizona
      This trial tests a new drug combination for adults with advanced NSCLC without specific genetic mutations. The treatment includes Dato-DXd, durvalumab, and carboplatin, which work together to kill cancer cells, boost the immune system, and stop cancer cell growth.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Small-cell Lung Cancer, Brain Metastases, Hepatitis B/C, Others

      1350 Participants Needed

      Telisotuzumab Vedotin vs. Docetaxel for Non-Small Cell Lung Cancer

      Phoenix, Arizona
      This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Leptomeningeal Disease, EGFR Mutations, Others
      Must Not Be Taking:Steroids, Anticonvulsants

      698 Participants Needed

      Durvalumab + Tremelimumab for Non-Small Cell Lung Cancer

      Scottsdale, Arizona
      This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Autoimmune Disorders, Others
      Must Not Be Taking:Steroids, Immunomodulatory Therapy

      1118 Participants Needed

      Radiation + Immunotherapy for Non-Small Cell Lung Cancer

      Phoenix, Arizona
      This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Auto-immune Disease, Pneumonitis, Hepatitis, Others
      Must Be Taking:Immunotherapy

      427 Participants Needed

      KB707 for Lung Cancer

      Scottsdale, Arizona
      The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707. Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase. Combination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks. All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:HIV, Active Brain Metastases, Autoimmune, Others
      Must Be Taking:Keytruda

      250 Participants Needed

      GMCI + Immunotherapy for Lung Cancer

      Phoenix, Arizona
      The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Heart Disease, HIV, Others
      Must Be Taking:Immune Checkpoint Inhibitors

      90 Participants Needed

      TNG456 + Abemaciclib for Solid Tumors

      Scottsdale, Arizona
      This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, Cardiovascular Disease, Others
      Must Not Be Taking:PRMT5 Inhibitors, MAT2A Inhibitors, CDK4/6 Inhibitors

      191 Participants Needed

      Pembrolizumab Combo for Lung Cancer

      Tempe, Arizona
      This trial is testing different combinations of cancer drugs to find the best treatment for patients with advanced lung cancer who haven't been treated before. The drugs help the immune system fight cancer or stop the cancer cells from growing.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Impairment, Active Infection, CNS Metastases, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Antineoplastics, Others

      318 Participants Needed

      Erlotinib + Cabozantinib for Non-Small Cell Lung Cancer

      Scottsdale, Arizona
      This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Prior Erlotinib, Major Thrombotic Events, Others
      Must Not Be Taking:Anticoagulants, CYP3A4 Inducers

      125 Participants Needed

      PF-07248144 for Breast Cancer

      Scottsdale, Arizona
      This trial is testing a new cancer drug called PF-07248144. It aims to find the best dose and see if it works better alone or with other cancer drugs. The study focuses on cancer patients who may not be responding well to current treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Major Surgery, Others
      Must Be Taking:LHRH Agonists

      320 Participants Needed

      Immunotherapy Combo for Lung Cancer

      Phoenix, Arizona
      This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      860 Participants Needed

      Chemotherapy + Bevacizumab for Non-Small Cell Lung Cancer

      Scottsdale, Arizona
      This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1501 Participants Needed

      LP-300 + Chemotherapy for Lung Adenocarcinoma EGFR

      Goodyear, Arizona
      This trial tests a new drug, LP-300, combined with two existing chemotherapy drugs in never smokers with a specific type of lung cancer who did not respond to previous treatments. The goal is to see if this combination improves survival by making the chemotherapy more effective.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Small Cell, Squamous Cell, Cardiac Issues, Others
      Must Not Be Taking:CYP2C19, P-gp Substrates

      90 Participants Needed

      ALE.P02 for Cancer

      Scottsdale, Arizona
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Non-squamous Cancers, Uncontrolled Diabetes, CNS Metastases, Others
      Must Not Be Taking:QT Drugs

      170 Participants Needed

      MRT-2359 for Solid Tumors

      Scottsdale, Arizona
      This trial tests a new drug called MRT-2359 that breaks down a protein in cancer cells. It targets patients with certain types of previously treated cancers. The drug aims to destroy a protein crucial for cancer cell survival, potentially stopping or slowing the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Malabsorption, CNS Involvement, Cardiac Disease, Others
      Must Be Taking:Fulvestrant, Enzalutamide

      174 Participants Needed

      Why Other Patients Applied

      "I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

      EQ
      Lung Cancer PatientAge: 70

      "My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

      OF
      Cholangiocarcinoma PatientAge: 54

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

      FR
      Lung Cancer PatientAge: 71

      "I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

      UM
      Pancreatic Cancer PatientAge: 48
      Match to a Lung Cancer Trial

      GEN1046 for Cancer

      Phoenix, Arizona
      The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo. This trial has 2 parts. The purpose of the first part is to find out if acasunlimab is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first part work against cancer when given alone and how well they work when given with pembrolizumab (with or without other chemotherapy) or docetaxel. Trial details include: * The average trial duration for an individual subject will be about 74 weeks. * The average treatment duration for an individual subject will be about 21 weeks. * The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Autoimmune Disease, Heart Failure, Others

      429 Participants Needed

      BMF-219 for Lung Cancer

      Goodyear, Arizona
      A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      90 Participants Needed

      Autogene Cevumeran + Atezolizumab for Cancer

      Scottsdale, Arizona
      This trial tests a personalized cancer vaccine and an immune-boosting drug in cancer patients. The vaccine teaches the body to attack cancer, while the drug helps immune cells find and kill hidden cancer cells. This approach aims to induce strong anti-tumor responses by selecting suitable vaccines based on the patient's existing immune system.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Liver Disease, CNS Metastases, Others
      Must Not Be Taking:MAOIs, Immunosuppressives

      272 Participants Needed

      NXP900 for Advanced Cancers

      Phoenix, Arizona
      This trial is testing a new drug called NXP900 to see how safe it is for people with advanced cancers. Researchers are trying different doses to find out which one works best without causing too many side effects. The goal is to determine the best dose for future studies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:HER2+ Malignancies, Brain Metastases, Others
      Must Be Taking:Bisphosphonates, GnRH Agonists

      140 Participants Needed

      IMM-6-415 for Solid Tumors

      Scottsdale, Arizona
      This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Disease, Diabetes, RVO, Others

      240 Participants Needed

      PRO1107 for Advanced Cancer

      Scottsdale, Arizona
      This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Active CNS Metastases, Others
      Must Not Be Taking:Strong CYP3A Inhibitors

      33 Participants Needed

      JAB-21822 + Cetuximab for Solid Tumors

      Phoenix, Arizona
      This trial is testing a new drug, JAB-21822, alone and with cetuximab in adults with advanced cancers that have a specific genetic change called KRAS G12C. The goal is to see if these treatments are safe and can stop the cancer from growing. Adagrasib is a related molecule that also has FDA approval for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Active Infection, HBV, HCV, Others

      100 Participants Needed

      Fc-Engineered Anti-CTLA-4 Monoclonal Antibody for Advanced Cancer

      Scottsdale, Arizona
      This trial is testing two new drugs that help the immune system fight cancer. It targets adults with advanced cancers that haven't responded to other treatments. The drugs work by blocking proteins that usually prevent the immune system from attacking cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Brain Metastases, Cardiovascular Disease, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppressives

      499 Participants Needed

      IMM-1-104 for Solid Cancers

      Scottsdale, Arizona
      This trial is testing a new drug called IMM-1-104 to see if it can help treat advanced cancers with specific genetic changes. The drug works by blocking signals that make cancer cells grow.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Disease, Rhabdomyolysis, Others

      209 Participants Needed

      TNG462 Combination for Lung and Pancreatic Cancer

      Scottsdale, Arizona
      TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a dose escalation phase and a dose expansion phase.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, CNS Metastases, Others
      Must Not Be Taking:PRMT5 Inhibitors, MAT2A Inhibitors

      133 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Lung Cancer clinical trials in Glendale, AZ pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Lung Cancer clinical trials in Glendale, AZ work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Cancer trials in Glendale, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Glendale, AZ for Lung Cancer is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Glendale, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Lung Cancer medical study in Glendale, AZ?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Lung Cancer clinical trials in Glendale, AZ?

      Most recently, we added BMS-986504 + Pembrolizumab + Chemotherapy for Lung Cancer, Multiple Treatments for Non-Small Cell Lung Cancer and Neladalkib for Non-Small Cell Lung Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Arizona

      Anxiety Clinical Trials in Arizona

      Schizophrenia Clinical Trials in Arizona

      ADHD Clinical Trials in Arizona

      Bipolar Disorder Clinical Trials in Arizona

      Multiple Sclerosis Clinical Trials in Arizona

      Autism Clinical Trials in Arizona

      Treatment Resistant Depression Clinical Trials in Arizona

      Borderline Personality Disorder Clinical Trials in Arizona

      Social Anxiety Disorder Clinical Trials in Arizona

      Parkinson's Disease Clinical Trials in Arizona

      Alzheimer's Disease Clinical Trials in Arizona

      By Location

      Clinical Trials near Phoenix, AZ

      Clinical Trials near Tucson, AZ

      Clinical Trials near Scottsdale, AZ

      Clinical Trials near Mesa, AZ

      Clinical Trials near Chandler, AZ

      Clinical Trials near Tempe, AZ

      Clinical Trials near Gilbert, AZ

      Clinical Trials near Glendale, AZ

      Clinical Trials near Peoria, AZ

      Clinical Trials near Sun City, AZ

      Clinical Trials near Goodyear, AZ

      Clinical Trials near Flagstaff, AZ

      Other People Viewed

      By Subject

      Top Prostate Cancer Clinical Trials near Glendale, AZ

      Top Clinical Trials near Glendale, AZ

      110 Colorectal Cancer Trials near Glendale, AZ

      138 Breast Cancer Trials near Glendale, AZ

      Top Alzheimer's Disease Clinical Trials near Glendale, AZ

      Top Lung Cancer Clinical Trials near Phoenix, AZ

      197 Clinical Paid Trials near Glendale, AZ

      20 Autism Trials near Glendale, AZ

      Top Prostate Cancer Clinical Trials near Phoenix, AZ

      Top Lung Cancer Clinical Trials near Austin, TX

      Top Lung Cancer Clinical Trials near Raleigh, NC

      Top Lung Cancer Clinical Trials near High Point, NC

      By Trial

      Sotorasib for Non-Small Cell Lung Cancer

      GT103 + Pembrolizumab for Non-Small Cell Lung Cancer

      MGY825 for Lung Cancer

      CivaSheet for Lung Cancer

      Pre-Surgical Respiratory Muscle Training for Lung Cancer

      Osimertinib + Necitumumab for Lung Cancer

      NIR Fluorescence-Guided Surgery for Early Stage Lung Cancer

      Immunotherapy + Local Consolidation Therapy for Lung Cancer

      Abemaciclib Combo for Lung Cancer or alternatively, if focusing on breast cancer: Abemaciclib Combo for Breast Cancer

      DS-1062a vs Docetaxel for Lung Cancer

      Radiation Therapy + Durvalumab for Lung Cancer

      Nivolumab + Plinabulin for Lung Cancer

      Related Searches

      Top Lung-cancer Clinical Trials near Los Angeles, CA

      Top Lung-cancer Clinical Trials near Baltimore, MD

      Top Clinical Trials near Ventura, CA

      Top Clinical Trials near Madison, WI

      Top Clinical Trials near Baltimore, MD

      Neuromodulation for Depression

      Omadacycline vs Moxifloxacin for Community-acquired Pneumonia

      Inhaled Treprostinil for Pulmonary Fibrosis

      CAR T-cell Therapy for Pediatric Leukemia & Lymphoma

      CatchU App for Fall Injury Prevention

      PRDR WBRT for Brain Cancer

      BI 1703880 + Ezabenlimab for Advanced Solid Tumors